Compare Biogen Inc (BIIB) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Innovative Industrial Properties Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Innovative Industrial Properties Inc trades at $58.2 (market cap $1.67B). The key difference: Biogen Inc is far larger — about 18× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 13.18% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | IIPR | |
|---|---|---|
Market Cap | $30.13B | $1.67B |
Sector | Health | Real Estate |
52-Week High | $216.63 | $64.67 |
52-Week Low | $128.93 | $44.58 |
Enterprise Value | $37.20B | $2.21B |
Dividend Yield | — | 13.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
IIPR trades at $57.69, showing modest daily gains of 0.37%. The stock presents mixed signals with bearish technical indicators but strong fundamentals including a P/E of 13.05 and net margin of 52.27%. Recent Q2 2026 earnings beat expectations with $1.36 EPS versus $1.02 forecast. The company maintains robust cash flow from operations at $198.19M and recently declared a $1.90 dividend for H1-2026.
Outlook remains cautiously optimistic despite technical weakness. The 9.09% dividend yield and attractive valuation metrics provide support, but declining revenue from $266M (2025) to $264M (2026) and tenant concentration risks in the cannabis REIT sector warrant monitoring. Analyst consensus leans Hold (54.55%) with institutional interest growing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
